October 14, 2021

ETERN Won the "Excellent Enterprise" Award of the 10th China Innovation & Entrepreneurship Competition Biomedical Section

On October 13, the 10th China Innovation and Entrepreneurship Competition Biomedical Section was successfully concluded in Hangzhou, China. ETERN Therapeutics stood out and won the "Excellent Enterprise" award.

ETERN focuses on developing global innovative small molecules targeting “undruggable” proteins. With the world-leading Protein Liquid-Liquid Phase Separation (LLPS) technology platform, ETERN has built multiple pipelines and advanced one to the clinical stage to provide new solutions to cancer patients. In this competition, ETERN received high recognition from the judges and won the award with its world's leading liquid-liquid phase separation (LLPS) platform and innovative SHP2 inhibitor.

The China Innovation & Entrepreneurship Competition is jointly organized by the Ministry of Science and Technology, the Ministry of Finance, the Ministry of Education, the Cyberspace Administration of China and the All-China Federation of Industry and Commerce. According to the organizers, there were 33,289 companies participating in this year’s competition. The 340 enterprises shortlisted were divided into 12 groups, each judged by five experts and investors who conducted professional review in terms of technology, marketing, team and finance.